The U.S. Food and Drug Administration has granted Fast Track designation to SRF388 for the treatment of patients with hepatocellular carcinoma (HCC), according to a press release.

“Liver cancer is the most rapidly increasing type of cancer in both men and women in the US, with incidences tripling since 1980. There is a significant need to expedite the development of new therapies to treat liver cancer as the five-year survival for patients with unresectable or metastatic liver cancer is…

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.